Skip to main content

Table 3 Parameters at baseline and during follow-up

From: Evaluation of cardiac function by global longitudinal strain before and after treatment with sofosbuvir-based regimens in HCV infected patients

Parameters

Group A

baseline mean (SD)

Month 1 mean (SD)

End of treatment mean (SD)

6th month of follow-up mean (SD)

p-value*

Group B

baseline mean (SD)

Month 1 mean (SD)

End of treatment mean (SD)

6th month of follow-up mean (SD)

p-value*

FIB-4

3.8 (3.6)

2.7 (1.8)

0.003

5.5 (5.3)

3.7 (4.7)

< 0.001

APRI SCORE

1.2 (1.1)

0.6 (0.9)

< 0.001

1.7 (1.8)

0.9 (2.1)

0.002

INR

1.1 (0.2)

1.1 (0.1)

0.111

1.1 (0.2)

1.1 (0.1)

0.435

α-fetoprotein (ng/mL)

12.8 (20.9)

7.8 (19.3)

< 0.001

19.5 (28.9)

5.9 (3.1)

0.014

Creatinine (mg/dL)

0.8 (0.2)

0.9 (0.2)

0.031

0.7 (0.1)

0.8 (0.1)

0.032

Glucose (mg/dL)

112 (29)

110.5 (30.8)

0.266

128.6 (41.7)

119.3 (31.7)

0.337

Haemoglobin (g/dL)

14.2 (2.2)

14.1 (2.1)

0.551

13.6 (1.9)

13.9 (1.8)

0.625

Cholesterol (mg/dL)

155.2 (30.8)

163.5 (29.8)

0.070

149.9 (38.1)

179.3 (46.2)

0.003

Triglycerides (mg/dL)

111.25 (46.12)

110.96 (46.49)

0.155

112.12 (39.64)

100.8 (46.73)

0.295

AST (UI/L)

59.2 (40.9)

24.8 (13.3)

22.9 (9.1)

25.6 (13.4)

< 0.001

68.7 (40.6)

29.8 (19.7)

23.8 (8.3)

24.3 (8.3)

< 0.001

ALT (UI/L)

65. (41.3)

21.7 (11.4)

18.3 (6.8)

20.5 (9.4)

< 0.001

69.7 (52.3)

24 (15.1)

20.5 (8.5)

20.3 (10)

< 0.001

Platelet (×10 [3]/mL)

166.8 (65.8)

183.4 (78.5)

171.1 (77.5)

167.1 (61.5)

0.399

139.3 (62.1)

161.2 (72.3)

153.9 (65.4)

150.2 (58.9)

0.779

Total bilirubin (mg/dL)

0.9 (0.7)

1.1 (0.7)

0.9 (0.8)

0.7 (0.5)

< 0.001

1 (0.8)

1 (0.7)

0.7 (0.6)

0.8 (0.5)

< 0.001

Ejection Fraction (%)

56.5 (3.1)

56.9 (3.5)

56.6 (2.5)

56.7 (2.8)

0.499

56.9 (2.9)

57 (3)

57.2 (3.2)

57.4 (3.6)

0.535

GLS (%)

−20.8 (2.8)

−21.4 (2.4)

−20.9 (2.6)

−20.3 (2.6)

0.031

−21.1 (2.4)

−20.7 (2.7)

−20.3 (2.8)

−20.1 (2.5)

0.097

  1. We compared baseline and 6th month of follow-up values of the two groups of treatment (group A = 3 months of treatment, group B = 6 months of treatment) with t-test for FIB-4, APRI SCORE, α-fetoprotein, creatinine, glucose, haemoglobin, cholesterol, and triglycerides. We use mixed-linear models to evaluate the linear trend of the other parameters
  2. --: the parameter is not available at this follow-up point